Can you provide the approval date for apotex's ruxolitinib?

What is Apotex's ruxolitinib?

Apotex is developing a generic version of ruxolitinib, the active ingredient in Incyte's Jakafi. It is intended as a bone marrow transplant conditioning agent or for myelofibrosis, polycythemia vera, and acute graft-versus-host disease.

When was Apotex's ruxolitinib approved?

FDA records show no approval for Apotex's ruxolitinib as of late 2024.

When does Apotex's rujolitinib patent expire?

Apotex has not disclosed its own patent filings for this product. The underlying patents protecting Incyte's Jakafi expire in 2027.

What competitors produce ruxolitinib?

Incyte holds the brand-name rights to ruxolitinib. Other generic manufacturers such as Hetero Labs, Sun Pharma, and Zydus are also pursuing generic versions.

What happens if the 2027 patent expires?

Once the 2027 basic compound patent falls away, multiple generics could launch simultaneously. Competitive pricing pressure would likely drop prices 80-90% from the current $16,000 per month brand price.

Can biosimilars enter before patent expiry?

Ruxolitinib is a small molecule drug, not a biologic. No biosimilar pathway applies.